M. Donnette

CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabine.

L. Ouafik, B. Lacarelle, J. Ciccolini, 2018, Blood advances.

Simultaneous determination of cytosine arabinoside and its metabolite uracil arabinoside in human plasma by LC-MS/MS: Application to pharmacokinetics-pharmacogenetics pilot study in LAM patients.

L. Ouafik, C. Solas, B. Lacarelle, 2019, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

A New Thienopyrimidinone Chemotype Shows Multistage Activity against Plasmodium falciparum, Including Artemisinin-Resistant Parasites

P. Roques, S. Rault, G. Snounou, 2021, Microbiology spectrum.

Determination of 5-azacitidine in human plasma by LC–MS/MS: application to pharmacokinetics pilot study in MDS/AML patients

L. Ouafik, J. Ciccolini, R. Costello, 2023, Cancer Chemotherapy and Pharmacology.

Pharmacokinetics and pharmacogenetics of liposomal cytarabine in AML patients treated with CPX-351.

L. Ouafik, B. Lacarelle, J. Ciccolini, 2021, Journal of controlled release : official journal of the Controlled Release Society.